ACTH Treatment for Management of Nephrotic Syndrome: A Systematic Review and Reappraisal

Ronith Chakraborty, Arul Mehta, Nikhil Nair, Lena Nemer, Rahul Jain, Hirva Joshi, Rupesh Raina, Ronith Chakraborty, Arul Mehta, Nikhil Nair, Lena Nemer, Rahul Jain, Hirva Joshi, Rupesh Raina

Abstract

Background: In recent years, the use of adrenocorticotropic hormone (ACTH) therapy for treatment of proteinuria due to nephrotic syndrome (NS) has been heavily explored. ACTH therapy, which comes in the natural (H. P. Acthar Gel) or synthetic (tetracosactide) form, has resulted in remission in patients with immunosuppressive and steroid-resistant NS. However, the exact efficacy of ACTH therapy in the NS etiologies, such as membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), lupus nephritis (LN), IgA nephropathy (IgAN), and membranoproliferative glomerulonephritis (MPGN), has not been determined.

Objective: This systematic review analyzed the published literature on ACTH therapy in various NS etiologies to determine its efficacy.

Methods: A comprehensive search of MEDLINE, EMBASE, and Cochrane databases was conducted for articles through June 2019. An additional search was performed on clinicaltrials.gov to search for additional trials and cross reference the results of our database search. The literature which studied synthetic or natural ACTH treatment in patients with known etiologies of NS was included. Studies were excluded when they consisted of a single case report or did not analyze the lone effect of ACTH in NS.

Results: The initial search yielded a total of 411 papers, and 22 papers were included. In 214 MN patients, there was an overall remission of 40% (85/214) and an overall remission of 43% (42/98) in FSGS patients. In other etiologies, there were overall remissions of 78% (11/14), 31% (5/16), 40% (16/40), and 62% (8/13) in MCD, LN, IgAN, and MPGN patients, respectively.

Conclusion: ACTH showed benefits in proteinuria reduction across all etiologies of NS. However, more randomized controlled studies with larger population sets and longer follow-ups are imperative to establish causal benefits. New studies into its efficacy in children are also necessary.

Conflict of interest statement

The authors declare no conflicts of interest.

Copyright © 2020 Ronith Chakraborty et al.

Figures

Figure 1
Figure 1
ACTH as a melanocortin receptor antagonist. Adapted from Gong [9].
Figure 2
Figure 2
ACTH binding to receptors on the kidney and immune cells [9, 11].
Figure 3
Figure 3
PRISMA flowchart showing studies considered for inclusion.

References

    1. Lieberman K. V., Pavlova-Wolf A. Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance. Journal of Nephrology. 2017;30(1):35–44. doi: 10.1007/s40620-016-0308-3.
    1. Madan A., Mijovic-Das S., Stankovic A., Teehan G., Milward A. S., Khastgir A. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrology. 2016;17(1):p. 37. doi: 10.1186/s12882-016-0241-7.
    1. Filippone E., Dopson S., Rivers D., et al. Adrenocorticotropic hormone analog use for podocytopathies. International Medical Case Reports Journal. 2016;9:125–133. doi: 10.2147/IMCRJ.S104899.
    1. Bomback A. S., Canetta P. A., Canetta A., et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. American Journal of Nephrology. 2012;36(1):58–67. doi: 10.1159/000339287.
    1. Bomback A. S., Tumlin J., Baranski J., et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Design, Development and Therapy. 2011;5:147–153. doi: 10.2147/DDDT.S17521.
    1. Khastgir A., Mijovic-Das S., Stankovic A., et al. HP acthar® gel in patients with IgA nephropathy, membranous lupus nephritis and minimal change disease: a retrospective case series. American Journal of Kidney Diseases. 2015;65(4):p. A49. doi: 10.1053/j.ajkd.2015.02.139.
    1. Berg A.-L., Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrology Dialysis Transplantation. 2004;19(5):1305–1307. doi: 10.1093/ndt/gfh110.
    1. Berg A.-L., Nilsson-Ehle P., Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney International. 1999;56(4):1534–1543. doi: 10.1046/j.1523-1755.1999.00675.x.
    1. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nature Reviews Nephrology. 2011;8(2):122–128. doi: 10.1038/nrneph.2011.190.
    1. Lindskog A., Ebefors K., Johansson M. E., et al. Melanocortin 1 receptor agonists reduce proteinuria. Journal of the American Society of Nephrology. 2010;21(8):1290–1298. doi: 10.1681/ASN.2009101025.
    1. Gong R. Leveraging melanocortin pathways to treat glomerular diseases. Advances in Chronic Kidney Disease. 2014;21(2):134–151. doi: 10.1053/j.ackd.2013.09.004.
    1. Berg A.-L., Rafnsson A. T., Johannsson M., Dallongeville J., Arnadottir M. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins. Metabolism. 2006;55(8):1083–1087. doi: 10.1016/j.metabol.2006.04.001.
    1. Lal R., Bell S., Challenger R., et al. Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: a comparison with intravenous methylprednisolone. The Journal of Clinical Pharmacology. 2016;56(2):195–202. doi: 10.1002/jcph.582.
    1. Ponticelli C., Passerini P., Salvadori M., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. American Journal of Kidney Diseases. 2006;47(2):233–240. doi: 10.1053/j.ajkd.2005.10.016.
    1. Lorusso P., Bottai A., Mangione E., Innocenti M., Cupisti A., Egidi M. F. Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study. International Journal of Nephrology and Renovascular Disease. 2015;8:7–12. doi: 10.2147/IJNRD.S74349.
    1. Van De Logt A.-E., Beerenhout C. H., Brink H. S., Van De Kerkhof J. J., Wetzels J. F., Hofstra J. M. Synthetic acth in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study. PLoS One. 2015;10(11) doi: 10.1371/journal.pone.0142033.e0142033
    1. Picardi L., Villa G., Galli F., et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clinical Nephrology. 2004;62(11):403–404. doi: 10.5414/cnp62403.
    1. Rauen T., Michaelis A., Floege J., Mertens P. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1–24. Clinical Nephrology. 2009;71:637–642. doi: 10.5414/CNP71637.
    1. Hladunewich M. A., Cattran D., Beck L. H., et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (h.p. acthar (r) gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrology Dialysis Transplantation. 2014;29(8):1570–1577. doi: 10.1093/ndt/gfu069.
    1. Mallincroft. The acthar for treatment of proteinuria in membranous nephropathy patients (chart) available from. 2019. .
    1. Tumlin J., Galphin C., Santos R., Rovin B. Safety and efficacy of combination acthar gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Kidney International Reports. 2017;2(5):924–932. doi: 10.1016/j.ekir.2017.05.015.
    1. Hogan J., Bomback A. S., Mehta K., et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clinical Journal of the American Society of Nephrology. 2013;8(12):2072–2081. doi: 10.2215/CJN.02840313.
    1. Alhamad T., Dieck M. J., Younus U., et al. ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation. Transplantation. 2018;103(1):202–209. doi: 10.1097/TP.0000000000002320.
    1. Zand L., Canetta P., Lafayette R., et al. An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression. Kidney International Reports. 2019;5(1):58–65. doi: 10.1016/j.ekir.2019.10.007.
    1. Berg A.-L., Dolinina J., Back S. E. Steroid replaced with ACTH treatment in FSGS patients. American Journal of Kidney Diseases. 2013;61(4):p. B25. doi: 10.1053/j.ajkd.2013.02.045.
    1. Fiechtner J., Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23(9):905–912. doi: 10.1177/0961203314532562.
    1. Chen Y., Schieppati A., Chen X., et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews. 2014;10 doi: 10.1002/14651858.CD004293.pub3.CD004293
    1. Dahan K., Debiec H., Plaisier E., et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. Journal of the American Society of Nephrology. 2017;28(1):348–358. doi: 10.1681/asn.2016040449.
    1. Fervenza F. C., Appel G. B., Barbour S. J., et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. The New England Journal of Medicine. 2019;381(381):36–46. doi: 10.1056/NEJMoa1814427.
    1. Dussol B., Morange S., Burtey S., et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. American Journal of Kidney Diseases. 2008;52(4):699–705. doi: 10.1053/j.ajkd.2008.04.013.
    1. Laurin L.-P., Gasim A. M., Poulton C. J., et al. Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS. Clinical Journal of the American Society of Nephrology. 2016;11(3):386–394. doi: 10.2215/CJN.07110615.
    1. Ren H., Shen P., Li X., Pan X., Zhang W., Chen N. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. American Journal of Nephrology. 2013;37(1):84–90. doi: 10.1159/000346256.
    1. Vivarelli M., Massella L., Ruggiero B., Emma F. Minimal change disease. Clinical Journal of the American Society of Nephrology. 2017;12(2):332–345. doi: 10.2215/cjn.05000516.
    1. Chapter 5: minimal-change disease in adults. Kidney International Supplements. 2011;2(2):177–180. doi: 10.1038/kisup.2012.18.
    1. Janardan J., Ooi K., Menahem S. Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy. Clinical Kidney Journal. 2014;7(3):293–295. doi: 10.1093/ckj/sfu022.
    1. Stohl W., Hilbert D. M. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nature Biotechnology. 2012;30(1):69–77. doi: 10.1038/nbt.2076.
    1. Access Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis & Rheumatology. 2014;66(11):3096–3104. doi: 10.1002/art.38790.
    1. Li X., Golubovsky J., Hui-Yuen J., et al. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: a retrospective study of patients. F1000Research. 2015;4:p. 1103. doi: 10.12688/f1000research.7192.2.
    1. Reid S., Cawthon P. M., Craig J. C., et al. Non‐immunosuppressive treatment for IgA nephropathy. Cochrane Database of Systematic Reviews. 2011;3 doi: 10.1002/14651858.CD003962.pub2.CD003962

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren